VPRIV (Velaglucerase Alfa)
Enzyme Replacement Therapy for Gaucher Disease Type 1
VPRIV (velaglucerase alfa) is a long-term enzyme replacement therapy (ERT) approved for the treatment of Gaucher disease type 1 in patients aged 4 years and older. It works by replacing the missing or defective glucocerebrosidase enzyme, thereby reducing harmful accumulation of glucocerebroside in cells throughout the body. VPRIV is administered as an intravenous infusion every two weeks under medical supervision.
Quick Facts
Key Takeaways
- VPRIV is a long-term enzyme replacement therapy specifically designed for Gaucher disease type 1, a rare genetic lysosomal storage disorder.
- The standard dose is 60 Units/kg administered as an intravenous infusion over 60 minutes every two weeks.
- Infusion-related reactions, including hypersensitivity and anaphylaxis, can occur – patients must be monitored during and after each infusion.
- Patients switching from other enzyme replacement therapies for Gaucher disease can transition to VPRIV at an equivalent dose and frequency.
- VPRIV is approved for use in patients aged 4 years and older, including children, adolescents, and the elderly.
What Is VPRIV and What Is It Used For?
Gaucher disease is a rare inherited genetic condition classified as a lysosomal storage disorder. It occurs when the body does not produce sufficient quantities of the enzyme glucocerebrosidase, or produces a defective version of the enzyme. Without properly functioning glucocerebrosidase, a fatty substance called glucocerebroside (also known as glucosylceramide) progressively accumulates inside cells, particularly within macrophages – a type of white blood cell found in the liver, spleen, bone marrow, and other organs.
This accumulation of glucocerebroside leads to the characteristic signs and symptoms of Gaucher disease, which may include an enlarged spleen (splenomegaly), an enlarged liver (hepatomegaly), low blood platelet counts (thrombocytopenia), anemia, bone disease including bone pain and fractures, and growth retardation in children. Type 1 is the most common form of Gaucher disease and does not typically involve the central nervous system, distinguishing it from the more severe types 2 and 3.
VPRIV contains velaglucerase alfa, a recombinant (gene-activated) form of the human glucocerebrosidase enzyme. Unlike some other enzyme replacement therapies that are produced in non-human cell lines, velaglucerase alfa is produced using a human fibroblast cell line (HT-1080). This production method results in a protein with human-type glycosylation, which may facilitate cellular uptake through mannose receptors on macrophages, the primary target cells in Gaucher disease.
By providing a functional replacement for the deficient enzyme, VPRIV helps the body break down the accumulated glucocerebroside, gradually reducing the burden of stored lipid in affected organs. Clinical studies have demonstrated that VPRIV treatment leads to meaningful improvements in hemoglobin levels, platelet counts, and reductions in liver and spleen volumes. These therapeutic benefits are maintained with continued long-term treatment.
VPRIV was first approved by the European Medicines Agency (EMA) in 2010 and has since become an established treatment option for patients with Gaucher disease type 1 worldwide. It is manufactured by Takeda Pharmaceuticals (formerly Shire Pharmaceuticals) and is available in more than 40 countries globally.
What Should You Know Before Taking VPRIV?
Contraindications
Do not use VPRIV if you have a known severe allergic reaction (hypersensitivity) to velaglucerase alfa or to any of the other ingredients in this medicine. The inactive ingredients include sucrose, sodium citrate dihydrate, citric acid monohydrate, and polysorbate 20. If you have experienced anaphylaxis or severe hypersensitivity to VPRIV in the past, the decision to rechallenge should be made with extreme caution and only under close medical supervision with appropriate resuscitation measures available.
Warnings and Precautions
Infusion-related reactions represent the most significant safety concern with VPRIV therapy. These reactions can occur during or shortly after the infusion and may manifest as hypersensitivity reactions with symptoms including nausea, skin rash, difficulty breathing, back pain, chest tightness, urticaria (hives), joint pain, or headache. Additional symptoms that have been reported include dizziness, elevated blood pressure, fatigue, fever, pruritus (itching), blurred vision, and vomiting.
If you experience any symptoms during or after an infusion, notify your healthcare provider immediately. In the event of a severe reaction such as anaphylaxis during home infusion, stop the infusion immediately, seek emergency medical attention, and contact your doctor. Your healthcare team may administer additional medications including antihistamines, antipyretics (fever reducers), and corticosteroids to treat or prevent future reactions.
If you have previously experienced infusion-related reactions with other enzyme replacement therapies for Gaucher disease (such as imiglucerase or taliglucerase alfa), inform your doctor before starting VPRIV. While cross-reactivity is not common, your healthcare provider may wish to take additional precautions during your initial infusions.
In some cases, patients may develop antibodies against VPRIV. These anti-drug antibodies can potentially reduce the effectiveness of the treatment or increase the risk of infusion-related reactions. If you experience a loss of treatment effect or increasingly severe infusion reactions, your doctor may order blood tests to check for the presence of these antibodies and determine the most appropriate course of action.
VPRIV should not be used in children younger than 4 years of age, as there is no clinical experience in this very young age group. For children and adolescents aged 4 to 17 years, VPRIV can be given at the same dose and frequency as in adults. Pediatric patients should be monitored for growth and development as part of routine Gaucher disease management.
Pregnancy and Breastfeeding
Gaucher disease may become more active during pregnancy and in the weeks following delivery. The increased metabolic demands of pregnancy can exacerbate symptoms such as bone crises, cytopenia, and hepatosplenomegaly. Women with Gaucher disease who are pregnant or planning to become pregnant should discuss the use of VPRIV with their specialist physician. The decision to continue, start, or discontinue enzyme replacement therapy during pregnancy must weigh the potential benefits of treatment against any theoretical risks to the fetus.
It is not known whether velaglucerase alfa passes into breast milk. If you are breastfeeding or planning to breastfeed, consult your doctor before using this medicine. Your healthcare provider will help you decide whether to discontinue breastfeeding or discontinue VPRIV therapy, taking into account the benefit of breastfeeding for the child and the benefit of VPRIV treatment for the mother.
Driving and Operating Machinery
VPRIV has no or negligible influence on the ability to drive and use machines. However, some infusion-related reactions such as dizziness or blurred vision may temporarily affect these abilities. If you experience such symptoms after an infusion, wait until they resolve before driving or operating machinery.
VPRIV contains 12.15 mg sodium per vial, which is equivalent to 0.6% of the WHO-recommended maximum daily sodium intake for adults. This should be taken into consideration by patients on a controlled sodium diet, particularly if multiple vials are required per infusion session.
How Does VPRIV Interact with Other Drugs?
Velaglucerase alfa is a recombinant human enzyme that is metabolized through normal protein degradation pathways. Because it does not interact with the cytochrome P450 enzyme system or other common drug-metabolizing pathways, the risk of pharmacokinetic drug interactions is considered to be very low. However, no formal drug interaction studies have been conducted with VPRIV in clinical trials.
VPRIV must not be infused simultaneously with other medications through the same intravenous line, as compatibility with other drug solutions has not been evaluated. If you require other intravenous medications, they should be administered through a separate infusion line or at a different time.
Patients with Gaucher disease often take multiple medications to manage various aspects of their condition. Common concomitant medications include bisphosphonates for bone disease, pain relievers, and blood products for severe cytopenias. While no specific interactions have been identified with these classes of medications, it remains important to keep your healthcare team fully informed about all treatments you receive.
| Medication Class | Interaction Level | Clinical Consideration |
|---|---|---|
| Other IV medications | Do Not Co-Infuse | Compatibility not evaluated; use separate IV lines |
| Other ERT for Gaucher disease | Switch Protocol Required | Transition under physician guidance; match initial dose to prior ERT |
| Substrate reduction therapy (e.g., eliglustat, miglustat) | Monitor | Combined use not extensively studied; specialist guidance required |
| Antihistamines / Corticosteroids | Supportive Use | May be given as pre-medication to prevent infusion reactions |
| Bisphosphonates | No Known Interaction | Often used concurrently for Gaucher-related bone disease |
What Is the Correct Dosage of VPRIV?
VPRIV should only be administered under the supervision of a physician experienced in the management of Gaucher disease. The physician determines the appropriate dose based on your body weight and clinical response. The standard recommended starting dose is 60 Units per kilogram of body weight, administered as an intravenous infusion over a period of 60 minutes once every two weeks.
Adults
Standard Adult Dosage
Dose: 60 Units/kg body weight
Route: Intravenous infusion
Duration: Over 60 minutes
Frequency: Every 2 weeks (14 days)
If you are currently receiving enzyme replacement therapy with another product for Gaucher disease and your doctor wishes to switch you to VPRIV, you may initially receive VPRIV at the same dose and dosing frequency as your current therapy. Your doctor will then monitor your treatment response and may adjust the dose upward or downward over time to achieve optimal clinical outcomes.
If you tolerate your infusions well in a clinical setting, your doctor or nurse may arrange for you to receive infusions at home. Home infusion must only be performed after you (or your caregiver) have received appropriate training from your healthcare team. During home infusion, a responsible adult must always be present. The dose and infusion rate should not be changed without agreement from your treating physician.
Children and Adolescents (4–17 years)
Pediatric Dosage
Dose: 60 Units/kg body weight (same as adults)
Route: Intravenous infusion
Duration: Over 60 minutes
Frequency: Every 2 weeks (14 days)
Note: Not recommended for children under 4 years of age.
Children and adolescents between 4 and 17 years of age receive the same weight-based dose as adults. Pediatric patients in clinical trials demonstrated similar pharmacokinetic profiles and treatment responses to adult patients, supporting the use of the same dosing regimen across age groups. Growth monitoring should be performed as part of standard Gaucher disease management in pediatric patients.
Elderly Patients (65 years and older)
No dose adjustment is necessary for elderly patients. VPRIV can be given to patients over 65 years of age at the same dose and frequency as other adult patients. However, as with all age groups, the treating physician should monitor treatment response and adjust the dose as clinically appropriate.
Missed Dose
If you miss a scheduled VPRIV infusion, contact your doctor or healthcare team as soon as possible to arrange a replacement infusion. Maintaining a regular infusion schedule is important for optimal disease management. Do not attempt to make up for a missed dose by doubling the next infusion.
Overdose
If you believe you have received too much VPRIV, contact your doctor immediately. There is limited clinical experience with doses higher than the recommended 60 Units/kg. In clinical trials, VPRIV has been administered at doses up to 60 Units/kg without dose-limiting toxicities. However, higher doses may increase the risk of infusion-related reactions. Your healthcare team will provide appropriate monitoring and supportive care as needed.
If you stop receiving VPRIV, your Gaucher disease symptoms may return or worsen over time. Do not discontinue treatment without first discussing it with your specialist physician. The decision to stop or modify treatment should be based on careful clinical assessment.
| Patient Group | Dose | Frequency | Notes |
|---|---|---|---|
| Adults (18+ years) | 60 Units/kg | Every 2 weeks | Dose may be adjusted based on treatment response |
| Children & Adolescents (4–17 years) | 60 Units/kg | Every 2 weeks | Same dosing as adults; not for use under 4 years |
| Elderly (65+ years) | 60 Units/kg | Every 2 weeks | No dose adjustment needed |
| Switching from other ERT | Match prior ERT dose | Match prior ERT schedule | Physician to adjust based on clinical response |
What Are the Side Effects of VPRIV?
Side effects associated with VPRIV have been characterized in clinical trials and post-marketing surveillance. The majority of adverse reactions are infusion-related, occurring during or shortly after the intravenous infusion. These reactions are generally mild to moderate in severity and often become less frequent with continued treatment as patients develop tolerance.
Commonly (may affect up to 1 in 10 people), patients experienced serious allergic reactions with difficulty breathing, chest tightness, nausea, swelling of the face, lips, tongue or throat (anaphylactic/anaphylactoid reactions). Allergic skin reactions such as urticaria (hives), severe rash, or pruritus (itching) are also common. If any of these occur, seek immediate medical attention.
Most side effects, including allergic reactions, occurred during the infusion or shortly after. These are called infusion-related reactions. If the reaction is severe, your healthcare provider at the clinic will immediately stop the infusion and begin appropriate medical treatment. If a severe infusion-related reaction such as anaphylaxis occurs during home administration, you should immediately stop the infusion, seek emergency medical help, and contact your doctor.
If reactions are severe and/or the medicine loses its efficacy, your doctor may order a blood test to check for antibodies that could affect the outcome of your treatment. Your doctor or nurse may decide to continue administering VPRIV even if you experience infusion-related reactions, provided that your condition is carefully monitored.
Very Common Side Effects
- Headache
- Dizziness
- Fever / elevated body temperature
- Back pain
- Joint pain (arthralgia)
- Fatigue
- Bone pain
- Weakness / asthenia
- Abdominal pain
Common Side Effects
- Anaphylactic/anaphylactoid reactions (serious allergic reactions)
- Urticaria (hives), severe rash, pruritus (itching)
- Nausea
- Chest tightness / chest discomfort
- Hypertension (elevated blood pressure)
- Flushing (skin redness)
- Tachycardia (rapid heartbeat)
- Prolonged bleeding time / easy bruising
- Hypotension (low blood pressure)
- Development of anti-VPRIV antibodies
Uncommon Side Effects
- Blurred vision
- Vomiting
Some patients receiving VPRIV may develop antibodies against the medicine. In clinical trials, anti-drug antibodies were detected in a proportion of patients, though antibody formation was generally transient and did not appear to be consistently associated with loss of efficacy or increased adverse events. Your doctor may periodically test for antibodies, especially if you experience a change in treatment response or worsening infusion reactions.
How Should You Store VPRIV?
Proper storage of VPRIV is essential to maintain the potency and safety of the medicine. Keep this medicine out of the sight and reach of children. Do not use VPRIV after the expiry date stated on the carton and label after "EXP." The expiry date refers to the last day of that month.
Unopened vials of VPRIV must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F to 46°F). The medicine must not be frozen at any time, as freezing can damage the protein structure and render the medication ineffective. Always keep the vial in the outer carton to protect it from light, as velaglucerase alfa is photosensitive.
Once reconstituted with sterile water for injection and diluted in 0.9% sodium chloride infusion solution, the prepared infusion should be used immediately. If immediate use is not possible, the reconstituted and diluted solution may be stored for up to 24 hours at 2°C to 8°C. From a microbiological standpoint, immediate use is preferred.
Do not use VPRIV if the reconstituted solution appears discolored or contains visible foreign particles. The solution should be clear to slightly opalescent and colorless. Any unused medicine or waste material should be disposed of in accordance with local requirements. Do not dispose of medicines in household waste or down the drain.
What Does VPRIV Contain?
VPRIV is supplied as a white to off-white lyophilized (freeze-dried) powder in a 20 mL glass vial. Each vial contains 400 Units of velaglucerase alfa as the active substance. The powder requires reconstitution with 4.3 mL of sterile water for injection before further dilution and intravenous administration.
After reconstitution, each milliliter of solution contains 100 Units of velaglucerase alfa. The extractable volume from each reconstituted vial is 4.0 mL (400 Units), with the remaining volume accounting for the necessary overfill to ensure accurate dose delivery.
Inactive Ingredients (Excipients)
- Sucrose – serves as a stabilizer and lyoprotectant, helping to maintain the structural integrity of velaglucerase alfa during the freeze-drying process and reconstitution
- Sodium citrate dihydrate – acts as a buffer to maintain the appropriate pH of the solution
- Citric acid monohydrate – works in conjunction with sodium citrate as part of the buffering system
- Polysorbate 20 – a surfactant that helps prevent protein aggregation and adsorption to surfaces
VPRIV is available in packs containing 1, 5, or 25 vials. Not all pack sizes may be marketed in every country. The total dose for infusion is calculated based on the patient's body weight and is diluted in 100 mL of 0.9% sodium chloride infusion solution. The infusion must be administered through a 0.2 or 0.22 micrometer in-line filter. VPRIV is for single use only; any unused solution remaining in the vial after dose withdrawal should be discarded.
| Parameter | Value |
|---|---|
| Vial strength | 400 Units per vial |
| Reconstitution volume | 4.3 mL sterile water for injection |
| Concentration after reconstitution | 100 Units/mL |
| Extractable volume | 4.0 mL (400 Units) |
| Final dilution volume | 100 mL of 0.9% NaCl |
| In-line filter | 0.2 or 0.22 µm |
| Infusion duration | 60 minutes |
Frequently Asked Questions About VPRIV
VPRIV (velaglucerase alfa) is used as long-term enzyme replacement therapy (ERT) for patients with Gaucher disease type 1. It replaces the missing or defective glucocerebrosidase enzyme, helping the body break down glucocerebroside – a fatty substance that accumulates in cells and causes symptoms such as enlarged spleen and liver, low blood counts, bone pain, and fatigue.
VPRIV is given as an intravenous infusion (drip) over 60 minutes, every two weeks. The powder is reconstituted with sterile water and diluted in 0.9% sodium chloride solution before infusion through a 0.2 or 0.22 micrometer filter. It is initially given in a clinic under medical supervision. After appropriate training, home infusion may be possible under physician approval.
The most common side effects are infusion-related reactions, including headache, dizziness, fever, back pain, joint pain, and fatigue. Other very common side effects include bone pain, weakness, and abdominal pain. Serious allergic reactions (anaphylaxis) can also occur but are less frequent. Most side effects occur during or shortly after the infusion and tend to become less frequent over time.
Yes, VPRIV can be given to children and adolescents aged 4 to 17 years at the same dose and frequency as adults (60 Units/kg every two weeks). It should not be used in children younger than 4 years due to lack of clinical experience in this age group. Pediatric patients should be monitored for growth and development alongside their Gaucher disease management.
Yes, patients currently receiving another enzyme replacement therapy for Gaucher disease (such as imiglucerase or taliglucerase alfa) can switch to VPRIV. The initial VPRIV dose and infusion frequency can be matched to the previous ERT regimen. Your doctor will monitor your treatment response after switching and may adjust the dose over time to ensure optimal clinical outcomes.
Unopened VPRIV vials should be stored in a refrigerator at 2–8°C (36–46°F), protected from light, and kept in the original carton. Do not freeze. After reconstitution and dilution, the prepared solution should be used immediately or stored for a maximum of 24 hours at 2–8°C. Do not use the solution if it appears discolored or contains particles.
References
- European Medicines Agency (EMA). VPRIV (velaglucerase alfa) – Summary of Product Characteristics. Last updated 2024. Available at: EMA VPRIV EPAR.
- U.S. Food and Drug Administration (FDA). VPRIV (velaglucerase alfa) Prescribing Information. Takeda Pharmaceuticals. 2010 (updated 2023).
- Zimran A, et al. “Velaglucerase alfa: a novel alternative for enzyme replacement therapy in Gaucher disease.” Blood Cells, Molecules, and Diseases. 2009;43(1):68–73.
- Gonzalez DE, et al. “Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study.” American Journal of Hematology. 2013;88(3):166–171.
- Pastores GM, et al. “A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of velaglucerase alfa treatment of adult and pediatric patients with type 1 Gaucher disease previously treated with imiglucerase.” Blood Cells, Molecules, and Diseases. 2014;53(4):253–260.
- Grabowski GA, et al. “Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry.” American Journal of Hematology. 2015;90(Suppl 1):S12–S18.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd list, 2023.
- Biegstraaten M, et al. “Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease.” Blood Cells, Molecules, and Diseases. 2018;68:203–208.
Editorial Team
Written by the iMedic Medical Editorial Team – specialists in clinical pharmacology, hematology, and rare diseases with documented academic background and clinical experience.
Reviewed by the iMedic Medical Review Board according to international guidelines (EMA, FDA, WHO) and the GRADE evidence framework.
Last medical review: | Evidence level: 1A – Based on systematic reviews, randomized controlled trials, and official regulatory agency documentation.
Learn more about our medical team | Read our editorial standards